Pandemic Still Weighs On Gilead’s HIV Business, But Signs Of Recovery
Company Calls Off Inhaled Remdesivir Program
Executive Summary
HIV PrEP and treatments saw increases in sales, though the US treatment market’s recovery was slower than expected and may need “several” quarters to return to pre-pandemic levels.
You may also be interested in...
COVID-19 Products Had Strong 2021, But Omicron Casts Shadow Over 2022
Evidence that the new variant dulls drugs and vaccines’ efficacy creates uncertainty for 2022, but new products are in the wings.
Coronavirus Update: Regeneron's REGEN-COV Authorized For Prevention
Regeneron's antibody cocktail gets emergency authorization for post-exposure prophylaxis from the US FDA. Daewoong's camostat shows efficacy in older patients in South Korean trial.
Gilead Teases Big Cancer Drug Readouts In Second Half
The company’s two approved cell therapies led growth in oncology. But despite oncology currently accounting for a small share of Gilead’s overall business, analysts expect big readouts later in the year.